journal article·2023-12-31Open access

Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy

Xiaofei Zhou, Yuetang Zhuang, Xiaohong Liu, Yaowen Gu, Junting Wang, Yuchen Shi, Li Zhang, Rui Li, Yelin Zhao, Hebing Chen, Jiao Li, Hongjuan Yao, Liang Li

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death. Therefore, we intend to explore novel strategies against PDAC. The exosomes-based biomimetic nanoparticle is an appealing candidate served as a drug carrier in cancer treatment, due to its inherit abilities. In the present study, we designed dasatinib-loaded hybrid exosomes by fusing human pancreatic cancer cells derived exosomes with dasatinib-loaded liposomes, followed by characterization for particle size (119.9 ± 6.10 nm) and zeta potential (-11.45 ± 2.24 mV). Major protein analysis from western blot techniques reveal the presence of exosome marker proteins CD9 and CD81. PEGylated hybrid exosomes showed pH-sensitive drug release in acidic condition, benefiting drug delivery to acidic cancer environment. Dasatinib-loaded hybrid exosomes exhibited significantly higher uptake rates and cytotoxicity to parent PDAC cells by two-sample t-test or by one-way ANOVA analysis of variance, as compared to free drug or liposomal formulations. The results from our computational analysis demonstrated that the drug-likeness, ADMET, and protein-ligand binding affinity of dasatinib are verified successfully. Cancer derived hybrid exosomes may serve as a potential therapeutic candidate for pancreatic cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Antibiotic Bioengineering of National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology (IMB), Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China

Department of Clinical Research Center, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China

Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Institute of Medical Information/Library, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Department of Chemistry, NY University, New York City, NY, USA

Beijing Institute of Radiation Medicine, Beijing, China

Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

Funding

National Natural Science Foundation of China · CAMS Innovation Fund for Medical Sciences · Drug Innovation Major Project of China · Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine

References (67)

Show source-provided references
1. 10.3322/caac.2170810.3322/caac.21708 ↗
2. 10.1002/cncr.3427310.1002/cncr.34273 ↗
3. 10.3390/cancers909012210.3390/cancers9090122 ↗
4. 10.1016/j.bbcan.2020.18846110.1016/j.bbcan.2020.188461 ↗
5. 10.1016/j.tcb.2011.12.00110.1016/j.tcb.2011.12.001 ↗
6. 10.18632/oncotarget.246210.18632/oncotarget.2462 ↗
7. 10.1007/s10930-015-9616-z10.1007/s10930-015-9616-z ↗
8. 10.1016/j.ajpath.2013.09.02710.1016/j.ajpath.2013.09.027 ↗
9. 10.1038/s41598-019-44569-610.1038/s41598-019-44569-6 ↗
10. 10.1016/j.biomaterials.2021.12105610.1016/j.biomaterials.2021.121056 ↗
11. 10.1021/jacs.8b0358410.1021/jacs.8b03584 ↗
12. 10.1038/s41467-019-11718-410.1038/s41467-019-11718-4 ↗
13. 10.1186/s12951-022-01675-410.1186/s12951-022-01675-4 ↗
14. 10.1155/2022/423411610.1155/2022/4234116 ↗
15. 10.1016/j.biomaterials.2021.12096410.1016/j.biomaterials.2021.120964 ↗
16. 10.1038/srep2193310.1038/srep21933 ↗
17. 10.1002/advs.20170061110.1002/advs.201700611 ↗
18. 10.1016/j.actbio.2019.05.05410.1016/j.actbio.2019.05.054 ↗
19. 10.1016/j.biomaterials.2021.12076110.1016/j.biomaterials.2021.120761 ↗
20. 10.1021/acsnano.8b0205310.1021/acsnano.8b02053 ↗
21. 10.1006/bbrc.1997.804310.1006/bbrc.1997.8043 ↗
22. 10.1016/j.ajpath.2011.12.02810.1016/j.ajpath.2011.12.028 ↗
23. 10.3892/ijo.2014.235710.3892/ijo.2014.2357 ↗
24. 10.1053/j.gastro.2010.03.03410.1053/j.gastro.2010.03.034 ↗
25. 10.1080/15384047.2019.157995610.1080/15384047.2019.1579956 ↗
26. 10.1080/10717544.2021.190575110.1080/10717544.2021.1905751 ↗
27. 10.18632/oncotarget.1043510.18632/oncotarget.10435 ↗
28. 10.1159/00048073710.1159/000480737 ↗
29. 10.1155/2023/233653610.1155/2023/2336536 ↗
30. 10.1016/j.biomaterials.2020.12036910.1016/j.biomaterials.2020.120369 ↗
31. 10.1016/j.actbio.2018.05.03110.1016/j.actbio.2018.05.031 ↗
32. 10.1016/j.ejps.2022.10619910.1016/j.ejps.2022.106199 ↗
33. 10.1093/nar/gkab25510.1093/nar/gkab255 ↗
34. 10.1016/s0169-409x(00)00129-010.1016/s0169-409x(00)00129-0 ↗
35. 10.1002/jcc.2133410.1002/jcc.21334 ↗
36. 10.1007/978-1-4939-7000-1_2610.1007/978-1-4939-7000-1_26 ↗
37. Landrum G. RDKit: a software suite for cheminformatics, computational chemistry, and predictive modeling. Greg Landrum. 2013;8:31.
38. DeLano WL. Pymol: an open-source molecular graphics tool. CCP4 Newslett Pro Crystallogr. 2002;40(1):82–92.
39. 10.1021/ci200227u10.1021/ci200227u ↗
40. 10.1634/theoncologist.2013-025510.1634/theoncologist.2013-0255 ↗
41. 10.3390/genes1108083510.3390/genes11080835 ↗
42. 10.1016/0011-2240(85)90184-110.1016/0011-2240(85)90184-1 ↗
43. 10.1007/s11095-013-1135-z10.1007/s11095-013-1135-z ↗
44. 10.1016/j.cryobiol.2007.08.00210.1016/j.cryobiol.2007.08.002 ↗
45. 10.1016/S0006-3495(96)79452-310.1016/S0006-3495(96)79452-3 ↗
46. 10.1080/09687689929450810.1080/096876899294508 ↗
47. 10.1088/1367-2630/aabb9610.1088/1367-2630/aabb96 ↗
48. 10.1186/s12964-021-00730-110.1186/s12964-021-00730-1 ↗
49. 10.1038/nrm.2017.12510.1038/nrm.2017.125 ↗
50. 10.1111/tra.1280310.1111/tra.12803 ↗
51. 10.1016/j.bbrc.2014.12.01510.1016/j.bbrc.2014.12.015 ↗
52. 10.1002/mabi.20210004210.1002/mabi.202100042 ↗
53. 10.1016/j.bbamem.2014.07.02610.1016/j.bbamem.2014.07.026 ↗
54. 10.3402/jev.v3.2464110.3402/jev.v3.24641 ↗
55. 10.1186/1471-2407-11-10810.1186/1471-2407-11-108 ↗
56. 10.1016/j.biocel.2012.06.01810.1016/j.biocel.2012.06.018 ↗
57. 10.1186/s12885-017-3958-110.1186/s12885-017-3958-1 ↗
58. 10.1074/jbc.M109.04115210.1074/jbc.M109.041152 ↗
59. 10.1038/s41467-021-23946-810.1038/s41467-021-23946-8 ↗
60. 10.1007/s13346-013-0176-510.1007/s13346-013-0176-5 ↗
61. Hong RL, Huang CJ, Tseng YL, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res. 1999;5(11):3645–3652.
62. 10.1081/lpr-12002031810.1081/lpr-120020318 ↗
63. 10.1042/BJ2003159410.1042/BJ20031594 ↗
64. 10.1002/advs.20200051510.1002/advs.202000515 ↗
65. 10.1126/sciadv.abc301310.1126/sciadv.abc3013 ↗
66. 10.1200/CCI.19.0014410.1200/CCI.19.00144 ↗
67. 10.1126/science.aav174110.1126/science.aav1741 ↗